On October 23, 2026, AARP reported on research presented at The Menopause Society’s 2026 Annual Meeting in San Diego. The meeting ran from October 20 to 24 and featured work on weight, brain fog, gastrointestinal symptoms and shared medical appointments.
Why the existing treatment boundary still matters
Weight loss is not an indication for menopause hormone therapy, lead author Regina Castaneda of Mayo Clinic Florida stated in The Menopause Society’s announcement. That existing clinical boundary is the starting point for reading the weight findings. The research raises a question about treatment response rather than announcing a new reason to prescribe hormone therapy.
How to read the GLP-1 and hormone-therapy findings
The Menopause Society reported a retrospective observational study examining weight loss among women taking semaglutide or tirzepatide. Its findings need to be read separately for each medicine.
- Who the researchers studied. The cohort included nearly 2,400 women taking semaglutide and nearly 1,500 taking tirzepatide. Participants were older than 45 and had a BMI above 27 kg/m². These details define the population behind the headline: women already taking particular medicines rather than a broad sample of everyone experiencing midlife body changes.
- What the semaglutide result showed. Hormone therapy was associated with significantly greater and sustained weight loss among semaglutide users. The wording matters because the researchers observed an association between treatment use and weight outcomes. The finding concerns a difference within this cohort rather than a newly tested prescribing strategy.
- Why tirzepatide needs its own reading. For tirzepatide users, the initial difference did not reach statistical significance at the end of the study. That result should remain visible beside the semaglutide finding rather than disappearing into a broad headline about GLP-1 medicines. The study does not support treating the medicines as interchangeable when describing this particular association.
- Where the evidence stops. The retrospective observational design cannot establish that hormone therapy caused the additional weight loss or rule out other explanations. The Society’s release supplies neither detailed effect sizes nor follow-up figures, so it cannot support a promised amount or duration of added weight loss. Castaneda said the findings need confirmation in prospective trials. The cohort’s age and BMI criteria also limit how broadly its results should be applied.
- What the finding contributes to the conversation. The Society’s medical director Stephanie Faubion described the possible relevance of menopause-specific factors in weight management. The useful distinction is between asking why treatment responses differ and assuming that a combination should become routine care. Keeping treatment discussions tied to the symptoms being addressed preserves that distinction without making weight the sole purpose of menopause care.
The most meaningful next question is therefore about evidence: would a study designed to test the association prospectively reproduce it? That is different from asking whether every woman using a GLP-1 medicine should also receive hormone therapy.
How to interpret the brain-fog findings
The Menopause Society’s announcement and AARP’s coverage also described a review involving the ADHD medicines lisdexamfetamine and atomoxetine.
- The reported improvement was specific. The review found improvements in women’s self-reported executive functioning. This describes how participants rated that aspect of their functioning. It should be reported as that particular outcome rather than compressed into a claim that cognition improved across the board.
- Other cognitive outcomes did not improve. The review did not find improvements in working memory or sustained attention. The Society characterised the evidence as preliminary, while AARP reported that it remains unclear whether these medicines address brain fog caused by hormonal fluctuations. Those distinctions belong together: a positive subjective outcome does not settle the wider question of treatment for menopause-related cognitive complaints.
- The clinical caution was explicit. AARP reported lead author Jennifer Tat’s advice against self-diagnosis and her recommendation to discuss symptoms with a clinician. She also noted that these medicines can have side effects. For readers thinking about memory changes in midlife, the research offers a focused discussion point rather than a medication choice to make independently.
This is also a reminder to keep the outcome being discussed visible. A report about executive-function ratings and a report about working memory are not interchangeable descriptions of the same finding. Reading them separately gives the research its proper meaning without dismissing women’s experiences.
Why the digestive findings resist a single hormonal explanation
The Menopause Society reported a University of Calgary study of more than 1,800 women aged 40 to 60. Its results describe reported symptoms across menopause stages.
- Bloating and gas stood out. Excessive bloating and gas were the most prevalent gastrointestinal symptoms in the study. For those symptoms, 65.6% of participants scored above the normal severity range. That percentage belongs to this study population and symptom measure rather than serving as a universal estimate for women in midlife.
- Menopause stage did not separate symptom severity. Gastrointestinal symptom severity did not differ significantly by menopause stage. The release also reported that no other gastrointestinal symptom was above the normal range. Together, these results make a more specific finding than a broad statement that digestive symptoms worsen as menopause progresses.
- Anxiety was part of the picture without becoming an explanation. Anxiety scores were highest during perimenopause. The findings do not establish that anxiety caused gastrointestinal symptoms or that digestive symptoms caused anxiety. Nor does this symptom study identify a treatment or a single cause for digestive changes.
The editorial value here is precision. Bloating can be a substantial concern without every digestive change being assigned to hormones. Reporting the symptom pattern accurately leaves room for an individual clinical assessment rather than turning the study into a ready-made diagnosis.
How shared appointments could broaden the care conversation
AARP’s report described a Stanford-led program examining a different question: whether the format of menopause care might support changes in daily behaviour.
- The program combined individual and group contact. It enrolled 28 women. After an initial individual appointment, 14 women participated in virtual group appointments once a week for six weeks. This was a specific care arrangement rather than a replacement of every individual visit with a group session.
- Participants later reported starting health-supporting behaviours. Six months later, group participants were more likely than peers receiving one-on-one care to report initiating behaviours related to exercise and sleep. The report also described behaviours supporting stress management and sexual function. These were reports of starting behaviours rather than evidence that every related health outcome improved.
- The appointment model remains under evaluation. AARP provided no numerical comparison of outcomes and said further clinical trials were needed to assess efficacy. Program lead Karen Adams described group discussion and follow-up as potential supports for behaviour change. The small program therefore raises a useful care-design question without establishing that group appointments are more effective.
This part of the meeting coverage deserves attention beside the medicine findings. It asks about the setting in which care happens rather than adding another treatment. That is a distinct research question with relevance to the wider experience of menopause care.
How to use the findings in a clinical conversation
The practical value of this research is in making the question more specific, not in creating a self-treatment protocol.
- Name the concern before selecting an explanation. The research packet supports describing the particular problem and when it occurs. Persistent bloating, attention difficulties and weight change are different concerns that deserve clear descriptions rather than being bundled into one menopause label.
- Describe the effect on daily life. Explaining how a concern affects everyday functioning gives a clinical conversation a clearer focus. The purpose is to communicate the experience accurately, not to match oneself to a study population or assume that a reported association explains an individual situation.
- Keep personal medicine decisions with qualified care. These meeting findings are conversation starters rather than reasons to start, stop or combine medicines independently. A clinician can discuss the specific concern and its treatment context without treating several separate research reports as one combined recommendation.
Why the next step is more precise care
For now, these findings should sharpen clinical questions about treatment response and symptom patterns while stronger studies test whether medicines or appointment models should change.
How Refemina helps
Research about medication combinations leaves a gap between an interesting finding and a personal treatment decision. Refemina gives women navigating midlife a research-led account of hormonal change and body composition, with clear distinctions between established evidence and promotional claims about supplements, hormones or weight loss.
Explore Resources
Sources
- Hormone Therapy May Increase Weight Loss Effectiveness ...
- 5 Menopause Research Updates That Could Shape Care
- ADHD Medications Offer Promise in Managing ...
- Excessive Bloating and Gas Plague Women Throughout the ...
